Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS

Precision oncology platform for personalised cannabinoid-based cancer therapies

Ziel

This project aims to develop and validate a precision oncology platform that predicts individual cancer patients’ responses to cannabinoid-based therapies. Cannabinoids show promising anti-tumour activity, but their clinical use remains limited by inconsistent outcomes, lack of predictive biomarkers, and the absence of tools that identify which patients may benefit. To address this gap, EndoVia Therapeutics will create a digital twin model of melanoma that integrates patient-derived tumour samples, multi-omics profiling of the endocannabinoid system (ECS), and mechanistic, AI-supported simulations of tumour–cannabinoid interactions.
The project will generate biopsy-derived melanoma models, stratified cannabinoid response datasets, and validated ECS biomarkers, which will serve as the biological foundation for training and testing the predictive engine. In vitro and in vivo studies, including patient-derived xenograft mouse models, will be used to refine and confirm the accuracy, safety, and translational relevance of the platform. The resulting preclinical demonstrator (TRL 6) will provide oncologists and drug developers with an evidence-based tool to guide compound selection, identify responders, and inform combination strategies with standard therapies.
In parallel, the project will establish the regulatory, clinical, and commercial pathways needed for future deployment, including a clear IP and FTO strategy, early engagement with clinical experts and industry partners, and a roadmap for IVDR/MDR compliance. By enabling data-driven personalisation of cannabinoid therapies, the project supports the objectives of the Horizon Europe Work Programme to advance precision medicine, accelerate translation of novel therapeutic approaches, and strengthen Europe’s leadership in AI-enabled oncology. The outcome will position the technology for early clinical validation and follow-on investment, contributing to more effective, personalised, and safer cancer treatment options.

Wissenschaftliches Gebiet (EuroSciVoc)

Schlüsselbegriffe

Programm/Programme

Thema/Themen

Finanzierungsplan

HORIZON-CSA - HORIZON Coordination and Support Actions

Alle im Rahmen dieses Finanzierungsinstruments finanzierten Projekte anzeigen

Aufforderung zur Vorschlagseinreichung

(öffnet in neuem Fenster) HORIZON-WIDERA-2025-02

Alle im Rahmen dieser Aufforderung zur Einreichung von Vorschlägen finanzierten Projekte anzeigen

Koordinator

EndoVia Therapeutics
Netto-EU-Beitrag
€ 344 050,00
Adresse
Ulica škofa Maksimilijana Držečnika 6
2000 Maribor
Slowenien
KMU
Ja
Region
Slovenija Vzhodna Slovenija Podravska
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Gesamtkosten
Keine Daten